Resmed Cdi revenue and financials
$31.59Change from previous close: −0.63%Absolute change: −$0.20
In the fiscal year ended June 2026, Resmed Cdi reported revenue of $5.65B (+9.85% year over year). Net income was $1.52B, a net margin of 26.9%.
Fiscal year ending in June. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +9.85%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +8.75%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 26.9%
- FY to Jun 2025: 27.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Jun 2026 | FY to Jun 2025 | FY to Jun 2024 | FY to Jun 2023 | FY to Jun 2022 |
|---|---|---|---|---|---|
| Total revenue | 5,653 | 5,146 | 4,685 | 4,223 | — |
| Cost of revenue | 2,202 | 2,091 | 2,030 | 1,867 | — |
| Gross profit | 3,452 | 3,055 | 2,655 | 2,356 | — |
| Selling, general and administrative | 1,120 | 993 | 917 | 874 | — |
| Research and development | 378 | 331 | 308 | 288 | — |
| Operating income | 1,908 | 1,685 | 1,384 | 1,152 | — |
| EBIT | 1,908 | 1,685 | 1,384 | 1,152 | — |
| EBITDA | 2,153 | 1,921 | 1,600 | 1,350 | — |
| Interest expense | — | — | 45.7 | 47.4 | 22.3 |
| Pre-tax income | 1,919 | 1,678 | 1,265 | 1,102 | — |
| Income tax | 396 | 277 | 244 | 204 | — |
| Net income | 1,523 | 1,401 | 1,021 | 898 | — |
| Net income to common shareholders | 1,523 | 1,401 | 1,021 | 898 | — |
| Basic EPS | 1.05 | 0.96 | 0.69 | 0.61 | — |
| Diluted EPS | 1.04 | 0.95 | 0.69 | 0.61 | — |
| Average shares (basic) | 1,455 | 1,467 | 1,470 | 1,468 | — |
| Average shares (diluted) | 1,461 | 1,473 | 1,476 | 1,475 | — |